Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.
Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recip...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2002
|
| _version_ | 1826303768657920000 |
|---|---|
| author | Lacy, MD Maguire, J Barcus, M Ling, J Bangs, M Gramzinski, R Basri, H Sismadi, P Miller, G Chulay, J Fryauff, D Hoffman, S Baird, J |
| author_facet | Lacy, MD Maguire, J Barcus, M Ling, J Bangs, M Gramzinski, R Basri, H Sismadi, P Miller, G Chulay, J Fryauff, D Hoffman, S Baird, J |
| author_sort | Lacy, MD |
| collection | OXFORD |
| description | Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians. |
| first_indexed | 2024-03-07T06:07:43Z |
| format | Journal article |
| id | oxford-uuid:ee6be04d-e4eb-42a0-8cdd-30e95099a32a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:07:43Z |
| publishDate | 2002 |
| record_format | dspace |
| spelling | oxford-uuid:ee6be04d-e4eb-42a0-8cdd-30e95099a32a2022-03-27T11:32:35ZAtovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ee6be04d-e4eb-42a0-8cdd-30e95099a32aEnglishSymplectic Elements at Oxford2002Lacy, MDMaguire, JBarcus, MLing, JBangs, MGramzinski, RBasri, HSismadi, PMiller, GChulay, JFryauff, DHoffman, SBaird, JThirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians. |
| spellingShingle | Lacy, MD Maguire, J Barcus, M Ling, J Bangs, M Gramzinski, R Basri, H Sismadi, P Miller, G Chulay, J Fryauff, D Hoffman, S Baird, J Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. |
| title | Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. |
| title_full | Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. |
| title_fullStr | Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. |
| title_full_unstemmed | Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. |
| title_short | Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. |
| title_sort | atovaquone proguanil therapy for plasmodium falciparum and plasmodium vivax malaria in indonesians who lack clinical immunity |
| work_keys_str_mv | AT lacymd atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT maguirej atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT barcusm atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT lingj atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT bangsm atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT gramzinskir atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT basrih atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT sismadip atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT millerg atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT chulayj atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT fryauffd atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT hoffmans atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity AT bairdj atovaquoneproguaniltherapyforplasmodiumfalciparumandplasmodiumvivaxmalariainindonesianswholackclinicalimmunity |